The VASCERN-VASCA working group diagnostic and management pathways for severe and/or rare infantile hemangiomas.

Algorithm Diagnosis Infantile hemangioma LUMBAR/PELVIS/SACRAL syndrome Large segmental hemangiomas Management Multifocal hemangiomas PHACES syndrome

Journal

European journal of medical genetics
ISSN: 1878-0849
Titre abrégé: Eur J Med Genet
Pays: Netherlands
ID NLM: 101247089

Informations de publication

Date de publication:
Jun 2022
Historique:
received: 01 11 2021
revised: 16 03 2022
accepted: 23 04 2022
pubmed: 30 4 2022
medline: 25 5 2022
entrez: 29 4 2022
Statut: ppublish

Résumé

The European Reference Network on Rare Multisystemic Vascular Diseases (VASCERN), is dedicated to gathering the best expertise in Europe and provide accessible cross-border healthcare to patients with rare vascular diseases. Infantile Hemangiomas (IH) are benign vascular tumors of infancy that rapidly growth in the first weeks of life, followed by stabilization and spontaneous regression. In rare cases the extent, the localization or the number of lesions may cause severe complications that need specific and careful management. Severe IH may be life-threatening due to airway obstruction, liver or cardiac failure or may harbor a risk of functional impairment, severe pain, and/or significant and permanent disfigurement. Rare IHs include syndromic variants associated with extracutaneous abnormalities (PHACE and LUMBAR syndromes), and large segmental hemangiomas. There are publications that focus on evidence-based medicine on propranolol treatment for IH and consensus statements on the management of rare infantile hemangiomas mostly focused on PHACES syndrome. The Vascular Anomalies Working Group (VASCA-WG) decided to develop a diagnostic and management pathway for severe and rare IHs with a Nominal Group Technique (NGT), a well-established, structured, multistep, facilitated group meeting technique used to generate consensus statements. The pathway was drawn following two face-to-face meetings and in multiple web meetings to facilitate discussion, and by mail to avoid the influence of most authoritative members. The VASCA-WG has produced this opinion statement reflecting strategies developed by experts and patient representatives on how to approach patients with severe and rare IH in a practical manner; we present an algorithmic view of the results of our work.

Identifiants

pubmed: 35487416
pii: S1769-7212(22)00098-2
doi: 10.1016/j.ejmg.2022.104517
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

104517

Informations de copyright

Copyright © 2022 The Authors. Published by Elsevier Masson SAS.. All rights reserved.

Auteurs

Andrea Diociaiuti (A)

Dermatology Unit and Genodermatosis Unit, Genetics and Rare Diseases Research Division, Bambino Gesù Children's Hospital, IRCCS, Piazza Sant'Onofrio 4, 00165, Rome, Italy. Electronic address: andrea.diociaiuti@opbg.net.

Eulalia Baselga (E)

Pediatric Dermatology, Hospital Sant Joan de Deu, Barcelona, Spain.

Laurence M Boon (LM)

Center for Vascular Anomalies, Division of Plastic Surgery, University Clinics Saint-Luc, University of Louvain, VASCERN VASCA European Reference Centre, Brussels, Belgium.

Anne Dompmartin (A)

Department of Dermatology, Université de Caen Basse Normandie, CHU Caen, Caen, France.

Veronika Dvorakova (V)

Paediatric Dermatology, Children's Health Ireland, (y)Clinical Medicine, Trinity College Dublin, Ireland.

May El Hachem (M)

Dermatology Unit and Genodermatosis Unit, Genetics and Rare Diseases Research Division, Bambino Gesù Children's Hospital, IRCCS, Piazza Sant'Onofrio 4, 00165, Rome, Italy.

Paolo Gasparella (P)

Department of Paediatric and Adolescent Surgery, Medical University of Graz, Graz, Austria.

Emir Haxhija (E)

Department of Paediatric and Adolescent Surgery, Medical University of Graz, Graz, Austria.

Nader Ghaffarpour (N)

Department of Plastic- and Craniofacial Surgery, Karolinska University Hospital, Stockholm, Sweden.

Kristiina Kyrklund (K)

Department of Pediatric Surgery, HUS Rare Disease Center, Helsinki University Hospital and University of Helsinki, Helsinki, Finland.

Alan D Irvine (AD)

Paediatric Dermatology, Children's Health Ireland, (y)Clinical Medicine, Trinity College Dublin, Ireland.

Friedrich G Kapp (FG)

Division of Pediatric Hematology and Oncology, Department of Pediatrics and Adolescent Medicine, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, 79106, Freiburg, Germany.

Jochen Rößler (J)

Division of Pediatric Hematology and Oncology, Department of Pediatrics and Adolescent Medicine, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, 79106, Freiburg, Germany; Division of Pediatric Hematology and Oncology, Department of Pediatrics, Inselspital, Bern University Hospital, University of Bern, Switzerland.

Päivi Salminen (P)

Department of Pediatric Surgery, HUS Rare Disease Center, Helsinki University Hospital and University of Helsinki, Helsinki, Finland.

Caroline van den Bosch (C)

Hevas, Patient Organisation for Vascular Anomalies, the Netherlands.

Carine van der Vleuten (C)

Department of Dermatology, Radboudumc Expertise Center for Haemangiomas and Congenital Vascular Malformations Nijmegen Hecovan, Radboud University Medical Center, Nijmegen, the Netherlands.

Leo Schultze Kool (LS)

Department of Radiology, Radboudumc Expertise Center for Haemangiomas and Congenital Vascular Malformations Nijmegen Hecovan, Radboud University Medical Center, Nijmegen, the Netherlands.

Miikka Vikkula (M)

Center for Vascular Anomalies, Division of Plastic Surgery, University Clinics Saint-Luc, University of Louvain, VASCERN VASCA European Reference Centre, Brussels, Belgium; Human Molecular Genetics, de Duve Institute, University of Louvain, Brussels, Belgium.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH